Search

Your search keyword '"Tornese, Gianluca"' showing total 4 results
Start Over Author "Tornese, Gianluca" Journal hormone research in paediatrics
4 results on '"Tornese, Gianluca"'

1. The 2021 European Training Requirements in Paediatric Endocrinology and Diabetes.

Author

Busiah, Kanetee, Peet, Aleksandr, Tornese, Gianluca, Weintrob, Naomi, Schulga, John, Hamza, Rasha T., Koletzko, Berthold, Russell, Rob Ross, Felice, Arthur, and Patel, Leena

Subjects
PEDIATRIC endocrinology, DIABETES in children, MEDICAL specialties & specialists, TASK forces, TERTIARY care
Abstract

The aims of the 2021 European Training Requirements (ETR) in Paediatric Endocrinology and Diabetes (PED) are to (1) provide standards to harmonize training programmes in PED between different European countries, (2) establish clearly defined standards of knowledge and skills required to practice PED at the tertiary care level, (3) foster the development of a network of competent tertiary care centres for PED in Europe and globally, and (4) improve the quality of care for children and adolescents requiring PED services. This ETR in PED specifies the requirements for training institutions, trainers, and trainees. It also provides the detailed syllabus/core content that trainees are expected to achieve in order to become competent independent clinicians in PED. References to consensus guidelines produced and/or endorsed by ESPE are included. The target users are trainees in PED, trainers, and all involved with quality assurance and accreditation. The process to develop and approve this 2021 ETR has been rigorous and involved trainees and consultants in paediatric and adult Endocrinology, ESPE (Syllabus Task Force, Education and Training Committee, Council), European Academy of Paediatrics (Tertiary Care Council, Assembly), European Board of Paediatrics, and Union of European Medical Specialists. Implementing the ETR will complement professional regulatory requirements for postgraduate training in PED in different countries and allow harmonizing standards across Europe. ETR is publicly available at www.eurospe.org/education/education-training-syllabus and at https://www.uems.eu/__data/assets/pdf_file/0007/133990/UEMS-2021.17-European-Training-Requirement-in-Paediatric-Endocrinology.pdf. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

4. MKRN3 Levels in Girls with Central Precocious Puberty during GnRHa Treatment: A Longitudinal Study

Author

Grazia Cirillo, Emanuele Miraglia del Giudice, Caterina Luongo, Anna Grandone, Marcella Sasso, Pierluigi Marzuillo, Gianluca Tornese, Adalgisa Festa, Grandone, Anna, Cirillo, Grazia, Sasso, Marcella, Tornese, Gianluca, Luongo, Caterina, Festa, Adalgisa, Marzuillo, Pierluigi, and Miraglia Del Giudice, Emanuele

Subjects
Male, 0301 basic medicine, Longitudinal study, Genotype, Ubiquitin-Protein Ligases, Endocrinology, Diabetes and Metabolism, Central precocious puberty, Puberty, Precocious, Physiology, Longitudinal Studie, 030209 endocrinology & metabolism, Puberty, Precociou, RING Finger Protein, Gonadotropin-Releasing Hormone, 03 medical and health sciences, Basal (phylogenetics), 0302 clinical medicine, Endocrinology, Humans, Medicine, Precocious puberty, In patient, Longitudinal Studies, Preschool, GnRH treatment, Child, Prospective cohort study, Children, Brain Diseases, Breast development, business.industry, Puberty, Brain Disease, Luteinizing Hormone, medicine.disease, MKRN3, Case-Control Studies, Child, Preschool, Female, Follicle Stimulating Hormone, Ribonucleoproteins, 030104 developmental biology, Pediatrics, Perinatology and Child Health, Precocious, Case-Control Studie, business, Human
Abstract

Background: Recently, mutations of makorin RING finger protein 3 (MKRN3) have been identified in familial central precocious puberty (CPP). Serum levels of this protein decline before the pubertal onset in healthy girls and boys and are lower in patients with CPP compared to prepubertal matched pairs. The aim of our study was to investigate longitudinal changes in circulating MKRN3 levels in patients with CPP before and during GnRH analogs (GnRHa) treatment. Methods: We performed a longitudinal prospective study. We enrolled 15 patients with CPP aged 7.2 years (range: 2–8) with age at breast development onset < 8 years and 12 control girls matched for the time from puberty onset (mean age 11.8 ± 1.2 years). Serum values of MKRN3, gonadotropins, and 17β-estradiol were evaluated before and during treatment with GnRHa (at 6 and 12 months). The MKRN3 gene was genotyped in CPP patients. In the girls from the control group, only basal levels were analyzed. Results: No MKRN3 mutations were found among CPP patients. MKRN3 levels declined significantly from baseline to 6 months of GnRHa treatment (p = 0.0007) and from 6 to 12 months of treatment (p = 0.003); MKRN3 levels at 6 months were significantly lower than in the control girls (p < 0.0001). Conclusions: We showed that girls with CPP had a decline in peripheral levels of MKRN3 during GnRHa treatment. Our data suggest a suppression of MKRN3 by continuous pharmacological administration of GnRHa.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results